Related Experiment Video
Updated: Dec 10, 2025
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Arne Kolstad1, Tim Illidge2, Nils Bolstad3
1Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
Abstract:
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.
Insights
New radioimmunotherapy shows promise for relapsed non-Hodgkin lymphoma. 177Lu-lilotomab satetraxetan achieved significant response rates in patients with indolent B-cell lymphoma, offering a new treatment option.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Immunotherapy
Background:
- Indolent non-Hodgkin lymphoma (iNHL) patients often face relapse after initial treatment.
- There is a critical need for novel therapies to improve outcomes and quality of life in relapsed/refractory iNHL.
- CD37-targeted radioimmunotherapy (RIT) presents a potential new avenue for treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of 177Lu-lilotomab satetraxetan in patients with relapsed/refractory indolent B-cell lymphoma.
- To assess response rates, duration of response, and adverse events associated with this novel RIT.
- To explore the potential of this therapy, particularly in patients with follicular lymphoma (FL) and those refractory to prior treatments.
Main Methods:
- A phase 1/2a study involving 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma.
- Patients received a single dose of 177Lu-lilotomab satetraxetan, preceded by rituximab and lilotomab.
- Adverse events, overall response rate (ORR), complete response (CR) rate, and duration of response were meticulously monitored.
Main Results:
- An overall response rate of 61% was observed, with 65% in follicular lymphoma (FL) patients.
- Complete response was achieved in 30% of all patients and 32% of FL patients with at least two prior therapies.
- Median duration of response was 13.6 months, extending to 32.0 months for complete responders.
- Common adverse events included reversible neutropenia (31.6%) and thrombocytopenia (26.3%).
Conclusions:
- 177Lu-lilotomab satetraxetan demonstrates significant efficacy in relapsed/refractory indolent B-cell lymphoma.
- This radioimmunotherapy offers a valuable alternative, especially for patients with comorbidities unsuitable for intensive treatments.
- The observed response rates and duration of response suggest a promising role for CD37-targeted RIT in managing iNHL.
More Related Videos
07:17Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
